Childhood cancers often originate from intricate molecular disruptions, where abnormal fusion proteins interact with a set of proteins responsible for gene regulation. These fusion proteins disturb the normal gene expression patterns by either activating genes that should be repressed or repressing genes that should be activated, ultimately leading to the development of cancer. Researchers at the University at Buffalo (UB) have delved into the underlying molecular mechanisms of this phenomenon, shedding light on how fusion proteins hijack key gene regulators to drive childhood cancer.
Published in Nature Communications, the study conducted by UB researchers reveals that fusion proteins and a gene regulatory protein complex engage through their disordered domains, which are known for their flexible and unstructured nature. Despite their lack of defined structure, these disordered domains interact specifically by forming liquid-like droplets that merge with each other. Priya Banerjee, the senior corresponding author of the study and an associate professor in the Department of Physics at UB, emphasizes the significance of these findings in elucidating the role of disordered protein regions in cancer and other human diseases.
Fusion proteins arise from chromosomal rearrangements, resulting in the formation of fusion genes. While not all fusion proteins lead to cancer, certain types, termed fusion oncoproteins, have the potential to disrupt gene activities significantly, driving uncontrolled cell growth and cancer development. Richoo Davis, the lead author of the study and a postdoc in Banerjee’s lab, highlights the critical role of fusion oncoproteins in pediatric cancers, where these proteins alone may be adequate to induce cancer, bypassing the need for multiple gene mutations typically required for cancer onset.
Previous studies have demonstrated that fusion oncoproteins interfere with a vital chromatin remodeler called the mammalian SWI/SNF complex, which is mutated in nearly 20% of all human cancers. The current research by Banerjee’s team aims to unravel the precise mechanism through which fusion oncoproteins hijack this complex. Their study builds upon earlier work and underscores the interaction between the disordered domains of both fusion oncoproteins and the mammalian SWI/SNF complex, challenging the conventional notion that protein interactions solely rely on structured domains.
The investigation focuses on prion-like domains within fusion oncoproteins and gene regulatory complexes, revealing that these domains form liquid-like droplets within the cell nucleus. These droplets facilitate the formation of molecular complexes between fusion oncoproteins and gene regulators, ultimately leading to aberrant gene expression conducive to cancer development. By utilizing a blue light-activated droplet-forming system, the researchers gained insights into the specificity of these molecular interactions and their role in promoting cancer progression.
The study suggests that the selectivity in molecular networking, particularly excluding disordered regions of repressor proteins from the droplets, is a critical mechanism through which fusion oncoproteins drive cancer development. Understanding these intricate molecular processes could pave the way for the development of targeted pharmaceutical interventions aimed at disrupting the abnormal interactions between fusion proteins and the SWI/SNF complex to combat cancer effectively. Banerjee underscores the importance of fundamental research in unraveling the molecular intricacies underlying fatal diseases like cancer, emphasizing the necessity of a comprehensive understanding of molecular mechanisms for successful therapeutic interventions.
Key Points:
– Fusion proteins in childhood cancer disrupt normal gene regulation mechanisms, leading to aberrant gene expression and cancer development.
– Disordered domains play a crucial role in mediating interactions between fusion proteins and gene regulatory complexes, contributing to cancer progression.
– Specific molecular networking events between fusion oncoproteins and regulatory proteins drive abnormal gene expression patterns, offering potential targets for cancer therapy.
– Understanding the molecular wiring underlying cancer development is essential for developing effective pharmaceutical interventions targeting fusion protein interactions.
Tags: regulatory
Read more on buffalo.edu